Oryzon Genomics SA
MAD:ORY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Oryzon Genomics SA
Total Equity
Oryzon Genomics SA
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Oryzon Genomics SA
MAD:ORY
|
Total Equity
€117.8m
|
CAGR 3-Years
18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
16%
|
|
|
Grifols SA
MAD:GRF
|
Total Equity
€5.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
5%
|
|
|
Pharma Mar SA
MAD:PHM
|
Total Equity
€251.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
20%
|
CAGR 10-Years
13%
|
|
Oryzon Genomics SA
Glance View
Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. The company is headquartered in Cornella De Llobregat, Barcelona and currently employs 44 full-time employees. The company went IPO on 2015-12-10. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The firm also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
See Also
What is Oryzon Genomics SA's Total Equity?
Total Equity
117.8m
EUR
Based on the financial report for Dec 31, 2025, Oryzon Genomics SA's Total Equity amounts to 117.8m EUR.
What is Oryzon Genomics SA's Total Equity growth rate?
Total Equity CAGR 10Y
16%
Over the last year, the Total Equity growth was 34%. The average annual Total Equity growth rates for Oryzon Genomics SA have been 18% over the past three years , 9% over the past five years , and 16% over the past ten years .
